Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology, redefining how targeted therapies are developed and applied in solid tumor treatment. By combining the targeting precision of monoclonal antibodies with highly potent cytotoxic payloads, ADCs enable selective delivery of therapeutics directly to tumor cells while reducing systemic exposure and limiting unintended effects on healthy tissue. [1][2] This targeted approach represents a significant shift away from traditional chemotherapy, which lacks specificity and often results in dose-limiting toxicities.
As advances in molecular biology, conjugation chemistry, and tumor biology converge, ADCs are increasingly positioned as a central component of precision oncology. Their ability to bridge biologics and small-molecule therapeutics has led to rapid expansion across multiple solid tumor indications, supported by a growing body of clinical evidence.
Mechanistic Foundations of ADCs
ADCs consist of three essential components: a monoclonal antibody, a chemical linker, and a cytotoxic payload. The antibody selectively binds to tumor-associated antigens expressed on cancer cells, enabling receptor-mediated internalization of the ADC complex. Once internalized, the ADC undergoes lysosomal degradation or linker cleavage through enzymatic, pH-dependent, or reduction-based mechanisms, releasing the payload into the cytoplasm, where it induces cell death through mechanisms such as DNA damage or microtubule inhibition. [2][3]
This targeted delivery system improves therapeutic specificity and reduces systemic toxicity compared to conventional cytotoxic agents. A critical feature of many modern ADCs is the “bystander effect,” where membrane-permeable payloads diffuse into neighboring tumor cells, enabling cytotoxic activity even in regions with heterogeneous antigen expression. [3] This is highly relevant in solid tumors, where intratumoral heterogeneity can limit the effectiveness of therapies that rely on uniform target expression.
Current Landscape of ADCs in Solid Tumors
The clinical landscape of ADCs in solid tumors has expanded rapidly, with multiple agents now approved and many more in development. According to a systematic review published in Critical Reviews in Oncology/Hematology, ADCs are “transforming clinical practice in oncology,” with a robust pipeline of candidates progressing through late-stage clinical trials. [1]
Approved ADCs targeting HER2, TROP-2, Nectin-4, and other antigens have demonstrated meaningful clinical benefit in breast, gastric, lung, and urothelial cancers. These therapies have shown improved response rates and progression-free survival, often in patients who have progressed on prior lines of treatment. [1][4] In some cases, ADCs have shifted treatment paradigms by offering targeted options in settings previously dominated by chemotherapy.
The broader oncology drug development landscape reflects strong momentum behind ADC innovation. Industry data indicate that ADCs represent one of the fastest-growing classes of anticancer therapeutics, with hundreds of investigational candidates spanning a wide range of tumor types and targets. [5] This expansion is associated with improved understanding of tumor biology and advances in engineering technologies that enhance ADC performance.
Advances in ADC Design and Analytical Considerations
Recent innovations in ADC design have focused on improving stability, specificity, and therapeutic index. Linker technologies have evolved to provide greater stability in circulation while enabling efficient payload release within tumor cells. Cleavable and non-cleavable linkers are now selected based on tumor biology, internalization kinetics, and desired pharmacodynamic effects. [3]
Site-specific conjugation methods have further improved ADC homogeneity, allowing for precise control of drug-to-antibody ratio (DAR). [7] This reduces variability in pharmacokinetics and enhances reproducibility across manufacturing batches. These advancements require rigorous analytical validation to confirm structural integrity, conjugation efficiency, and stability throughout the product lifecycle.
Analytical validation is particularly critical for ADCs due to their structural complexity. Advanced analytical techniques – including liquid chromatography, mass spectrometry, and capillary electrophoresis – are used to characterize key attributes such as DAR distribution, aggregation, and degradation pathways [6]. These methods support regulatory compliance and help optimize therapeutic performance by maintaining reliable product quality.
Payload innovation has also expanded significantly. While early ADCs relied on microtubule inhibitors such as auristatins and maytansinoids, newer payloads include agents that interfere with DNA replication, such as topoisomerase inhibitors and pyrrolobenzodiazepines. [3]. These agents offer increased potency and can be effective at lower intracellular concentrations, enhancing the therapeutic index.
Challenges: Resistance, Toxicity, and Tumor Heterogeneity
Despite their promise, ADCs face several challenges that limit their full clinical potential. Resistance mechanisms are increasingly recognized and may include downregulation of target antigen expression, impaired internalization, alterations in intracellular trafficking, and increased drug efflux via transport proteins [4]. Additional resistance mechanisms may include linker instability leading to premature payload release and intracellular payload metabolism that reduces cytotoxic activity. These mechanisms reduce effective payload delivery and can lead to treatment failure.
Toxicity remains another key concern. While ADCs are designed to minimize unintended effects, toxicity can arise from both on-target off-tumor activity, where target antigens are expressed in normal tissues, and off-target mechanisms such as premature linker cleavage or systemic release of cytotoxic payload. Clinical studies have reported adverse events including hematologic toxicity, hepatotoxicity, peripheral neuropathy, and interstitial lung disease. [4] Managing these toxicities is critical to maintaining dose intensity and treatment adherence.
Tumor heterogeneity further complicates ADC efficacy. Variability in antigen expression both within and between tumors can limit target engagement. Although the bystander effect helps address this issue, it may also contribute to off-target toxicity in surrounding healthy tissues. Understanding and overcoming these challenges remains a major focus of ongoing research.
Expanding Applications and Combination Strategies
The future of ADC therapy in solid tumors lies in combination strategies and next-generation designs. Combining ADCs with immune checkpoint inhibitors, targeted therapies, or chemotherapy is an area of active investigation aimed at enhancing antitumor activity and overcoming resistance. [7]
ADC-induced tumor cell death can increase antigen presentation and stimulate immune responses, providing a strong rationale for combining ADCs with immunotherapy. Additionally, combining ADCs with agents that target DNA repair pathways or tumor microenvironment components may further improve outcomes.
Next-generation ADCs are being developed with enhanced linker stability, novel payloads, and bispecific targeting capabilities. These designs aim to improve tumor selectivity, reduce toxicity, and expand the range of targetable antigens. Advances in computational modeling and biomarker identification are also contributing to more precise ADC development.
Future Directions in Precision Oncology
ADCs are increasingly central to precision oncology strategies, where treatment is tailored based on tumor-specific biomarkers. Improved diagnostic tools and molecular profiling techniques are enabling better identification of patients who are most likely to benefit from ADC therapies.
Ongoing clinical trials are exploring ADCs in earlier lines of therapy, as well as in combination regimens. These studies will play a key role in defining the optimal use of ADCs across different tumor types and disease stages.
An umbrella review published in BMC Cancer describes ADCs as a possible “rising star” in oncology, highlighting their ability to combine targeting precision with potent cytotoxic activity to reshape treatment paradigms [8]. As next-generation ADCs enter clinical practice, they are expected to further expand the therapeutic landscape and improve patient outcomes.
References
[1] Filis P, Zerdes I, Soumala T, Matikas A, Foukakis T. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review. Crit Rev Oncol Hematol. 2023;185:104189. doi:10.1016/j.critrevonc.2023.104189. [Article]
[2] Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. Jpn J Clin Oncol. 2024;54(8):837–. doi:10.1093/jjco/hyad161. [Article]
[3] Antibody–drug conjugates: A review of approved drugs and their mechanisms. Cancers (Basel). 2023;15(15):3886. doi:10.3390/cancers15153886. [Article]
[4] Toxicity and efficacy of antibody–drug conjugates in advanced solid tumors. ESMO Open. 2025;10:101442. doi:10.1016/j.esmoop.2025.101442. [Article]
[5] The oncology drug development landscape. CrownBio. 2023. [Article]
[6] Analytical development and validation considerations for antibody-drug conjugates. Pharmaceutics. 2024;17(12):1581. doi:10.3390/pharmaceutics17121581. [Article]
[7] Antibody-drug conjugates in cancer therapy: current perspectives and future directions. Front Cell Dev Biol. 2025;13:1669592. doi:10.3389/fcell.2025.1669592. [Article]
[8] Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses. BMC Cancer. 2025;25:13726. doi:10.1186/s12885-025-13726-8. [Article]
Featured image © 2026 CH/JCO Used with permission.
